Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 332 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
332 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with advanced malignancies, primarily HR+/HER2− advanced breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor (phase II limited to ≤2 prior endocrine lines for advanced disease and no prior chemotherapy/ADC in the advanced setting), with additional phase I cohorts for CCNE1-amplified solid tumors and metastatic castration-resistant prostate cancer. Patients receive the first-in-human investigational agent GVV858 (target/mechanism not publicly specified) as monotherapy or combined with endocrine therapy—fulvestrant (and letrozole in phase I), with phase II evaluating two GVV858 dose regimens plus fulvestrant.
ClinicalTrials.gov ID: NCT07288359
TrialFetch AI summary: Adults with metastatic or locally advanced solid tumors (including interest in TNBC) that have progressed after or are ineligible for standard therapy, with ECOG 0–1, measurable disease, adequate organ/cardiac function, and no significant cardiac disease/QTc prolongation, active >grade 1 neuropathy, or prior MMAE- or SORT1-targeted therapy. Participants receive PQ203, a once-weekly IV SORT1-targeting peptide–drug conjugate delivering the microtubule inhibitor MMAE to SORT1-expressing tumor cells, in dose-escalation/optimization to establish RP2D and assess preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07190469
TrialFetch AI summary: Enrolls adults with locally advanced/metastatic/unresectable solid tumors harboring ERBB2 (HER2) activating alterations, NRG1 fusions, or HER2 overexpression, with expansion cohorts for ERBB2-mutant NSCLC with brain metastases and ERBB2-mutant or HER2-overexpressing breast cancer with brain metastases ± leptomeningeal disease. Patients receive oral CGT4255, an investigational EGFR-sparing selective HER2 tyrosine kinase inhibitor designed to cover multiple oncogenic HER2 mutations with CNS penetration, given at escalating/selected doses.
ClinicalTrials.gov ID: NCT07361562
TrialFetch AI summary: Adults with ECOG 0–1 locally advanced unresectable or metastatic solid tumors (including NSCLC without actionable alterations, urothelial carcinoma, gastric/GEJ cancer, and HER2-negative breast cancer) in selected treatment settings, including 2L+ NSCLC and post–enfortumab vedotin+pembrolizumab urothelial carcinoma, plus first-line metastatic NSCLC (adenocarcinoma) and urothelial cohorts. Patients receive IV ASP2998, a first-in-human TROP2-targeting antibody–drug conjugate, as monotherapy or combined with pembrolizumab and/or carboplatin, and/or with enfortumab vedotin (urothelial cohorts), in 21-day cycles until progression or toxicity.
ClinicalTrials.gov ID: NCT07287995
TrialFetch AI summary: For adults with locally advanced or metastatic breast cancer (ECOG 0–1) previously treated with standard subtype-appropriate therapy (including prior endocrine therapy + CDK4/6 inhibitor for ER+/HER2−), enrolling molecularly defined cohorts: ER+/HER2−, ER+/HER2− with FGFR1 amplification, and luminal androgen receptor–subtype TNBC (AR ≥10% by IHC), generally with measurable disease and available tumor tissue. Patients receive oral BBI-940, a first-in-human kinesin molecular degrader designed to disrupt mitotic/ecDNA segregation, as monotherapy or (in ER+/HER2− without ESR1 mutation) in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07408089
TrialFetch AI summary: Adults with advanced/unresectable or metastatic solid tumors that have progressed after, are intolerant to, or lack standard systemic options (ECOG 0–1; measurable disease; excluding prior B7-H3–targeted therapy, prior topoisomerase inhibitor ADCs, significant ILD/pneumonitis, uncontrolled infection, or active/untreated CNS metastases). Patients receive SYS6043, an IV q3-week B7-H3 (CD276)–targeted antibody–drug conjugate delivering a cytotoxic payload to B7-H3–expressing tumor cells, with expansion cohorts planned in ES-SCLC, HR+/HER2− breast cancer, mCRPC, and ovarian cancer.
ClinicalTrials.gov ID: NCT07424547
TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808